- Home
- NMRA vs CANG Comparison
NMRA vs CANG Comparison
Compare NMRA & CANG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMRA | CANG |
|---|---|---|
| Founded | 2019 | 2010 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | | Computer Software: Prepackaged Software |
| Sector | | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 424.4M | 457.2M |
| IPO Year | 2023 | 2018 |
Fundamental Metrics
Financial Performance| Metric | NMRA | CANG |
|---|---|---|
| Price | $2.11 | $1.39 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 1 |
| Target Price | ★ $8.00 | $3.00 |
| AVG Volume (30 Days) | ★ 2.4M | 1.0M |
| Earning Date | 03-02-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $621,628,844.00 |
| Revenue This Year | N/A | $4,371.16 |
| Revenue Next Year | N/A | $13.27 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 1534.99 |
| 52 Week Low | $0.61 | $1.12 |
| 52 Week High | $3.25 | $2.10 |
Technical Indicators
Market Signals| Indicator | NMRA | CANG |
|---|---|---|
| Relative Strength Index (RSI) | 53.06 | 42.78 |
| Support Level | $1.84 | $1.34 |
| Resistance Level | $2.20 | $1.47 |
| Average True Range (ATR) | 0.25 | 0.13 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 56.54 | 10.71 |
Price Performance
Historical ComparisonAbout NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
About CANG Cango Inc. each representing two (2)
Cango Inc through its subsidiaries, variable interest entities (VIEs), and subsidiaries of the VIEs, are principally engaged in the bitcoin mining business, and the automobile trading transaction, automotive financing facilitation, and aftermarket service facilitation businesses (collectively, the automobile and related businesses). The Company conducts the bitcoin mining business mainly through its subsidiaries, and the automobile and associated businesses are conducted through the Company's VIEs and the subsidiaries of the VIEs. The company derives the majority of its revenue from the bitcoin mining business.